GPX3 Variant Genotype Affects the Risk of Developing Severe Forms of COVID-19
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms242216151 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Marko Markovic und 13 weiteren Autor:innen. Beteiligte Einrichtung: Clinic of Infectious and Tropical Diseases, University Clinical Centre of Serbia, 11000 Belgrade, Serbia. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science Fund of the Republic of Serbia.
Abstract (Originalsprache)
In SARS-CoV-2 infection, excessive activation of the immune system intensively increases reactive oxygen species levels, causing harmful hyperinflammatory and oxidative state cumulative effects which may contribute to COVID-19 severity. Therefore, we assumed that antioxidant genetic profile, independently and complemented with laboratory markers, modulates COVID-19 severity. The study included 265 COVID-19 patients. Polymorphism of GSTM1, GSTT1, Nrf2 rs6721961, GSTM3 rs1332018, GPX3 rs8177412, GSTP1 rs1695, GSTO1 rs4925, GSTO2 rs156697, SOD2 rs4880 and GPX1 rs1050450 genes was determined with appropriate PCR-based methods. Inflammation (interleukin-6, CRP, fibrinogen, ferritin) and organ damage (urea, creatinine, transaminases and LDH) markers, complete blood count and coagulation status (d-dimer, fibrinogen) were measured. We found significant association for COVID-19 progression for patients with lymphocytes below 1.0 × 109/L (OR = 2.97, p = 0.002). Increased IL-6 and CRP were also associated with disease progression (OR = 8.52, p = 0.001, and OR = 10.97, p < 0.001, respectively), as well as elevated plasma AST and LDH (OR = 2.25, p = 0.021, and OR = 4.76, p < 0.001, respectively). Of all the examined polymorphisms, we found significant association with the risk of developing severe forms of COVID-19 for GPX3 rs8177412 variant genotype (OR = 2.42, p = 0.032). This finding could be of particular importance in the future, complementing other diagnostic tools for prediction of COVID-19 disease course.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinic of Infectious and Tropical Diseases, University Clinical Centre of Serbia, 11000 Belgrade, Serbia.
- Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
- Institute of Medical Statistics and Informatics, 11000 Belgrade, Serbia.
- Institute of Medical and Clinical Biochemistry, 11000 Belgrade, Serbia.
- Centre for Excellence for Redox Medicine, Pasterova 2, 11000 Belgrade, Serbia.
- Clinic of Neurology, University Clinical Centre of Serbia, 11000 Belgrade, Serbia.
ORCID-Profile: Marko Markovic, Jovan Ranin, Zoran Bukumiric, Djurdja Jerotic, Ana Savic-Radojevic, Marija Pljesa-Ercegovac, Tatjana Djukic, Ivana Milosevic, Tatjana Simic, Vesna Coric
Förderung
- Science Fund of the Republic of Serbia
Zitieren
APA
Markovic, M., Ranin, J., Bukumiric, Z., Jerotic, D., Savic-Radojevic, A., Pljesa-Ercegovac, M., Djukic, T., Ercegovac, M., Asanin, M., Milosevic, I., Stevanovic, G., Simic, T., Coric, V., & Matic, M. (2023). GPX3 Variant Genotype Affects the Risk of Developing Severe Forms of COVID-19. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242216151
Vancouver
Markovic M, Ranin J, Bukumiric Z, Jerotic D, Savic-Radojevic A, Pljesa-Ercegovac M, et al. GPX3 Variant Genotype Affects the Risk of Developing Severe Forms of COVID-19. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242216151
BibTeX
@article{Markovic2023,
author = {Markovic, Marko and Ranin, Jovan and Bukumiric, Zoran and Jerotic, Djurdja and Savic-Radojevic, Ana and Pljesa-Ercegovac, Marija and Djukic, Tatjana and Ercegovac, Marko and Asanin, Milika and Milosevic, Ivana and Stevanovic, Goran and Simic, Tatjana and Coric, Vesna and Matic, Marija},
title = {GPX3 Variant Genotype Affects the Risk of Developing Severe Forms of COVID-19},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms242216151}
}
EUVIMED